US biotech major Gilead Sciences (Nasdaq: GILD) announced today that Michael Quigley has joined the company as senior vice president, Research Biology, bringing to the role deep experience in oncology and immuno-oncology biology.
Dr Quigley joins Gilead from Bristol-Myers Squibb (NYSE: BMY), where most recently he was VP, Tumor Microenvironment Modulation Thematic Research Center and site head of the Redwood City, California location. In that role, Dr Quigley was responsible for setting strategy for Bristol-Myers Squibb’s oncology discovery portfolio and business development activities, overseeing target identification, validation and preclinical development of large and small molecule therapies. He received a PhD in Immunology from Duke University and conducted his post-doctoral research at the Dana Farber Cancer Institute, Department of Pediatric Oncology.
New role for Linda Higgins
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze